202 related articles for article (PubMed ID: 8738200)
1. Fluconazole versus oral polyenes in the prophylaxis of immunocompromised patients: a cost-minimization analysis.
Wakerly L; Craig AM; Malek M; Hoffmeyer U; Lloyd A; Valette F; Phillips R; Zabihollah M
J Hosp Infect; 1996 May; 33(1):35-48. PubMed ID: 8738200
[TBL] [Abstract][Full Text] [Related]
2. Costs of antifungal prophylaxis after bone marrow transplantation. A model comparing oral fluconazole, liposomal amphotericin and oral polyenes as prophylaxis against oropharyngeal infections.
Stewart A; Powles R; Hewetson M; Antrum J; Richardson C; Mehta J
Pharmacoeconomics; 1995 Oct; 8(4):350-61. PubMed ID: 10155676
[TBL] [Abstract][Full Text] [Related]
3. Fluconazole for antifungal prophylaxis in chemotherapy-induced neutropenia.
Preston SL; Briceland LL
Am J Health Syst Pharm; 1995 Jan; 52(2):164-73; quiz 205-6. PubMed ID: 12879543
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials.
Kanda Y; Yamamoto R; Chizuka A; Hamaki T; Suguro M; Arai C; Matsuyama T; Takezako N; Miwa A; Kern W; Kami M; Akiyama H; Hirai H; Togawa A
Cancer; 2000 Oct; 89(7):1611-25. PubMed ID: 11013378
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
Sohn HS; Lee TJ; Kim J; Kim D
Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
[TBL] [Abstract][Full Text] [Related]
6. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group.
Ninane J
Eur J Clin Microbiol Infect Dis; 1994 Apr; 13(4):330-7. PubMed ID: 7794307
[TBL] [Abstract][Full Text] [Related]
7. Posaconazole vs fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in Greece.
Athanasakis K; Petrakis I; Kyriopoulos J
J Med Econ; 2013; 16(5):678-84. PubMed ID: 23448409
[TBL] [Abstract][Full Text] [Related]
8. Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia.
Fung M; Kim J; Marty FM; Schwarzinger M; Koo S
PLoS One; 2015; 10(11):e0140930. PubMed ID: 26554923
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
Stam WB; O'Sullivan AK; Rijnders B; Lugtenburg E; Span LF; Janssen JJ; Jansen JP
Eur J Haematol; 2008 Dec; 81(6):467-74. PubMed ID: 18754857
[TBL] [Abstract][Full Text] [Related]
10. [Cost effectiveness of posaconazole versus fluconazole/itraconazole in the prophylactic treatment of invasive fungal infections in Mexico].
Rely K; Alexandre PK; Escudero GS
Value Health; 2011; 14(5 Suppl 1):S39-42. PubMed ID: 21839897
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients.
Scharfstein JA; Paltiel AD; Freedberg KA
Med Decis Making; 1997; 17(4):373-81. PubMed ID: 9343795
[TBL] [Abstract][Full Text] [Related]
12. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
[TBL] [Abstract][Full Text] [Related]
13. Systemic fungal infections: major problems in cancer patients.
Powles RL; Mehta J
Indian J Cancer; 1994 Sep; 31(3):180-4. PubMed ID: 8557296
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections.
de Vries R; Daenen S; Tolley K; Glasmacher A; Prentice A; Howells S; Christopherson H; de Jong-van den Berg LT; Postma MJ
Pharmacoeconomics; 2008; 26(1):75-90. PubMed ID: 18088160
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
Schonfeld W; Wang Cheng J; Tong KB; Seifeldin R
Clin Ther; 2008 May; 30(5):964-73. PubMed ID: 18555943
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy.
Nomura K; Kawasugi K; Morimoto T
Eur J Cancer Care (Engl); 2006 Mar; 15(1):44-50. PubMed ID: 16441676
[TBL] [Abstract][Full Text] [Related]
17. Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia.
Collins CD; Ellis JJ; Kaul DR
Am J Health Syst Pharm; 2008 Dec; 65(23):2237-43. PubMed ID: 19020192
[TBL] [Abstract][Full Text] [Related]
18. Management of fungal infection in neutropenic patients with fluconazole.
Brammer KW
Haematol Blood Transfus; 1990; 33():546-50. PubMed ID: 2182447
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group.
Philpott-Howard JN; Wade JJ; Mufti GJ; Brammer KW; Ehninger G
J Antimicrob Chemother; 1993 Jun; 31(6):973-84. PubMed ID: 8360134
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
